Apellis Pharmaceuticals, Inc. ( APLS) - Stock Earnings
APLS Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q3 | 215.7 million USD | 458.6 million USD |
| 2025Q4 | -59.0 million USD | 199.9 million USD |
| 2026Q1 | 18.7 million USD | 268.3 million USD |
| 2026Q2 Est. | — | — |
| 2026Q3 Est. | — | — |
| 2026Q4 Est. | — | — |
APLS Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -528.6 million USD | 396.6 million USD |
| 2024 | -197.9 million USD | 781.4 million USD |
| 2025 | 22.4 million USD | 1.0 billion USD |
| 2026 Est. | — | — |
APLS
Price: $41.03
52 week price:
Earnings Per Share: 1.07 USD
P/E Ratio: 38.34
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.2 million
Ebitda: -11.6 millionMarket Capitalization: 5.3 billion